We characterize the immunological features associated with clinical outcomes and show that patients with LACC that display a brisk immune infiltrate in the proximity of PD-L1+ tumor cells, activated, tumor-infiltrating T cells endowed with costimulatory markers, and enrichment in IFN-related pathways benefit from the combination treatment. The gene discussed is CD274; the disease is neoplasm.